Advanced Drug Delivery Reviews

Article	Citations
Liposome composition in drug delivery design, synthesis, characterization, and clinical application	315
COVID-19 vaccines: The status and perspectives in delivery points of view	247
Self-assembled mRNA vaccines	243
The role of lipid components in lipid nanoparticles for vaccines and gene therapy	196
Supramolecular engineering of hydrogels for drug delivery	167
To PEGylate or not to PEGylate: Immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternatives	163
Pharmaceutical electrospinning and 3D printing scaffold design for bone regeneration	161
Overcoming barriers by local drug delivery with liposomes	156
Non-viral COVID-19 vaccine delivery systems	154
Recombinant protein vaccines, a proven approach against coronavirus pandemics	153
DNA hydrogel-based gene editing and drug delivery systems	153
Translating 3D printed pharmaceuticals: From hype to real-world clinical applications	147
Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers	133
Dosing extracellular vesicles	129
Peptide and peptide-based inhibitors of SARS-CoV-2 entry	126
Frontiers in the treatment of glioblastoma: Past, present and emerging	124
RNAi-based therapeutics and tumor targeted delivery in cancer	122
Nucleic acid delivery for therapeutic applications	122
Fibronectin in development and wound healing	121
Recent advances in design of antimicrobial peptides and polypeptides toward clinical translation	120
Advances in powder bed fusion 3D printing in drug delivery and healthcare	117
Rational designs of in vivo CRISPR-Cas delivery systems	116
Connected healthcare: Improving patient care using digital health technologies	115
Advanced engineered nanoparticulate platforms to address key biological barriers for delivering chemotherapeutic agents to target sites	109
Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis	108

Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy	108
Opening doors with ultrasound and microbubbles: Beating biological barriers to promote drug delivery	106
Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment	104
Machine learning directed drug formulation development	99
Cardiac fibrosis: Myofibroblast-mediated pathological regulation and drug delivery strategies	96
Antimicrobial peptides towards clinical application: Delivery and formulation	93
Targeting drug delivery with light: A highly focused approach	92
Peptide-based supramolecular hydrogels for local drug delivery	92
Clinical translation of nanomedicines: Challenges, opportunities, and keys	92
(Macro)molecular self-assembly for hydrogel drug delivery	91
Engineering the drug carrier biointerface to overcome biological barriers to drug delivery	90
Nanoscale MOFs: From synthesis to drug delivery and theranostics applications	89
Extracellular vesicles as a drug delivery system: A systematic review of preclinical studies	88
Approaches to surface engineering of extracellular vesicles	87
Polymeric drug delivery systems by additive manufacturing	87
Topical drug delivery: History, percutaneous absorption, and product development	85
Extracellular vesicles for tissue repair and regeneration: Evidence, challenges and opportunities	84
Harnessing artificial intelligence for the next generation of 3D printed medicines	84
Near-infrared fluorescence imaging in immunotherapy	84
Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network	83
Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment	82
Oral delivery of natural active small molecules by polymeric nanoparticles for the treatment of inflammatory bowel diseases	82
Emerging 3D printing technologies for drug delivery devices: Current status and future perspective	82
Technology insight: Plant-derived vesicles—How far from the clinical biotherapeutics and therapeutic drug carriers?	81
Challenges of fused deposition modeling 3D printing in pharmaceutical applications: Where are we now?	80
Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis	78
Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants	78
Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge	77
Microneedle-Mediated Vaccination: Innovation and Translation	76
Clinically established biodegradable long acting injectables: An industry perspective	73
Let’s talk about sex: Differences in drug therapy in males and females	73
Coupling hot melt extrusion and fused deposition modeling: Critical properties for successful performance	73
SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?	72
The effects of protein corona on in vivo fate of nanocarriers	72
Advances in gene-based vaccine platforms to address the COVID-19 pandemic	71
Traditional herbal medicine and nanomedicine: Converging disciplines to improve therapeutic efficacy and human health	71
An overview of in vitro, ex vivo and in vivo models for studying the transport of drugs across intestinal barriers	71
Target specific tight junction modulators	71
Biomedical engineering of two-dimensional MXenes	70
Nanocarrier vaccines for SARS-CoV-2	69
Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic	69
Photodynamic and antibiotic therapy in combination against bacterial infections: efficacy, determinants, mechanisms, and future perspectives	67
Tumor-activated carrier-free prodrug nanoparticles for targeted cancer Immunotherapy: Preclinical evidence for safe and effective drug delivery	67
Why nanoparticles prefer liver macrophage cell uptake in vivo	67
Dawn of lipid nanoparticles in lymph node targeting: Potential in cancer immunotherapy	66
A call for the standardised reporting of factors affecting the exogenous loading of extracellular vesicles with therapeutic cargos	66
Delivery of STING agonists for adjuvanting subunit vaccines	66
The past, present, and future of breast cancer models for nanomedicine development	66
Separation, characterization, and standardization of extracellular vesicles for drug delivery applications	65
3D printing as a transformative tool for microneedle systems: Recent advances, manufacturing considerations and market potential	65

Vaccine delivery systems toward lymph nodes	65
Multifaceted role of phyto-derived polyphenols in nanodrug delivery systems	65
Biomembrane-based nanostructures for cancer targeting and therapy: From synthetic liposomes to natural biomembranes and membrane-vesicles	64
Mesoporous silica nanoparticles for pulmonary drug delivery	64
Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis	63
Targeting the blood-brain barrier for the delivery of stroke therapies	63
Emerging innate biological properties of nano-drug delivery systems: A focus on PAMAM dendrimers and their clinical potential	62
Imaging technology of the lymphatic system	62
Technological advances towards extracellular vesicles mass production	62
Polymeric nano- and microparticulate drug delivery systems for treatment of biofilms	62
Shape memory materials and 4D printing in pharmaceutics	62
The tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives	61
Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy	60
Scaled preparation of extracellular vesicles from conditioned media	59
Ultrasound and microbubbles to beat barriers in tumors: Improving delivery of nanomedicine	59
Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across	59
Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms	59
Nanomedicine for brain cancer	58
Exploring interactions between extracellular vesicles and cells for innovative drug delivery system design	58
Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection	58
In situ activation of therapeutics through bioorthogonal catalysis	58
Non-spherical micro- and nanoparticles for drug delivery: Progress over 15 years	58
Therapeutic targeting of the oncogenic Wnt signaling pathway for treating colorectal cancer and other colonic disorders	57
Tumor-on-chip modeling of organ-specific cancer and metastasis	57
Tumor microenvironment-responsive dynamic inorganic nanoassemblies for cancer imaging and treatment	57
α-Amino acid N-carboxyanhydride (NCA)-derived synthetic polypeptides for nucleic acids delivery	57
Cell-penetrating peptides in protein mimicry and cancer therapeutics	56
The in vivo fate of polymeric micelles	56
Metal-organic frameworks for therapeutic gas delivery	55
Advances in mRNA non-viral delivery approaches	55
Engineering interferons and interleukins for cancer immunotherapy	55
2D materials-based nanomedicine: From discovery to applications	54
High-throughput proteomics and AI for cancer biomarker discovery	54
Smart gating porous particles as new carriers for drug delivery	54
Dry powder pharmaceutical biologics for inhalation therapy	53
Polymeric long-acting drug delivery systems (LADDS) for treatment of chronic diseases: Inserts, patches, wafers, and implants	53
Pharmaceutical applications of powder-based binder jet 3D printing process – A review	53
Novel antimicrobial agents for combating antibiotic-resistant bacteria	53
Translating complexity and heterogeneity of pancreatic tumor: 3D in vitro to in vivo models	52
In silico T cell epitope identification for SARS-CoV-2: Progress and perspectives	51
A quantitative view on multivalent nanomedicine targeting	51
Clinical translation of advanced colonic drug delivery technologies	51
Self-assembly of protein-polymer conjugates for drug delivery	50
Tumor microenvironment remodeling-based penetration strategies to amplify nanodrug accessibility to tumor parenchyma	50
Stabilizers and their interaction with formulation components in frozen and freeze-dried protein formulations	50
Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities	49
Nucleic acid delivery with extracellular vesicles	48
Defensins: The natural peptide antibiotic	48
Responsive optical probes for deep-tissue imaging: Photoacoustics and second near-infrared fluorescence	48
Extracellular vesicles as antigen carriers for novel vaccination avenues	48
Bacterial extracellular vesicles: Understanding biology promotes applications as nanopharmaceuticals	48
Optimizing synthetic nucleic acid and protein nanocarriers: The chemical evolution approach	48
Multifunctional nanotheranostics for near infrared optical imaging-guided treatment of brain tumors	47
Exosomes as natural delivery carriers for programmable therapeutic nucleic acid nanoparticles (NANPs)	47
Emerging strategies in developing multifunctional nanomaterials for cancer nanotheranostics	47
Nanotechnology-empowered vaccine delivery for enhancing CD8+ T cells-mediated cellular immunity	47
Electroactive material-based biosensors for detection and drug delivery	47
Bioinspired drug delivery strategies for repurposing conventional antibiotics against intracellular infections	46
Advancing pharmacy and healthcare with virtual digital technologies	46
Autophagy in the cancer-immunity dialogue	46
Automation and data-driven design of polymer therapeutics	46
Listening to drug delivery and responses via photoacoustic imaging	45
The promising interplay between sonodynamic therapy and nanomedicine	45
Integration of personalized drug delivery systems into digital health	45
Synthetic multi-layer nanoparticles for CRISPR-Cas9 genome editing	45
Nano-delivery to the lung - by inhalation or other routes and why nano when micro is largely sufficient?	45
Stability of lyophilized and spray dried vaccine formulations	44
Red blood cells: The metamorphosis of a neglected carrier into the natural mothership for artificial nanocarriers	44
Microarray patches enable the development of skin-targeted vaccines against COVID-19	44
Oral nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome	44
Role of CFD based in silico modelling in establishing an in vitro-in vivo correlation of aerosol deposition in the respiratory tract	44
Modulating the foreign body response of implants for diabetes treatment	44
Overcoming the rising incidence and evolving mechanisms of antibiotic resistance by novel drug delivery approaches – An overview	44
Extracellular vesicles as delivery systems at nano-/micro-scale	44
Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood–brain barrier (BBB) to manage neurological disorders	44
Gene- and RNAi-activated scaffolds for bone tissue engineering: Current progress and future directions	43
Advances and future perspectives in epithelial drug delivery	43
Mastering the Gram-negative bacterial barrier – Chemical approaches to increase bacterial bioavailability of antibiotics	43
Extrahepatic targeting of lipid nanoparticles in vivo with intracellular targeting for future nanomedicines	43
Microarray patches: Breaking down the barriers to contraceptive care and HIV prevention for women across the globe	43

A review of emerging technologies enabling improved solid oral dosage form manufacturing and processing	42
Nanovaccines with cell-derived components for cancer immunotherapy	42
Development of extracellular vesicle-based medicinal products: A position paper of the group “Extracellular Vesicle translatiOn to clinicaL perspectiVEs – EVOLVE France”	42
Polymer- and lipid-based nanocarriers for ocular drug delivery: Current status and future perspectives	42
Development and aging of the lymphatic vascular system	42
Building three-dimensional lung models for studying pharmacokinetics of inhaled drugs	42
GO-based antibacterial composites: Application and design strategies	41
Stealth and pseudo-stealth nanocarriers	41
Human skin equivalents: Impaired barrier function in relation to the lipid and protein properties of the stratum corneum	41
Towards controlled drug delivery in brain tumors with microbubble-enhanced focused ultrasound	41
Rationally designed drug delivery systems for the local treatment of resected glioblastoma	41
Two-Dimensional Nanomaterial-based catalytic Medicine: Theories, advanced catalyst and system design	40
Artificial intelligence to bring nanomedicine to life	40
Engineering of stimuli-responsive self-assembled biomimetic nanoparticles	40
The RNA-binding protein HuR in human cancer: A friend or foe?	40
Advances of nanomedicines in breast cancer metastasis treatment targeting different metastatic stages	40
Supercritical fluid (SCF)-assisted fabrication of carrier-free drugs: An eco-friendly welcome to active pharmaceutical ingredients (APIs)	40
Understanding molecular mechanisms of biologics drug delivery and stability from NMR spectroscopy	40
In vitro and ex vivo models in inhalation biopharmaceutical research — advances, challenges and future perspectives	39
Nucleic acid nanoparticles (NANPs) as molecular tools to direct desirable and avoid undesirable immunological effects	39
Formulation strategies to improve the efficacy of intestinal permeation enhancers,	39
Extracellular vesicles for the treatment of central nervous system diseases	39
Delivering more for less: nanosized, minimal-carrier and pharmacoactive drug delivery systems	39
Ferritin nanocage: A promising and designable multi-module platform for constructing dynamic nanoassembly-based drug nanocarrier	39
Organ-on-a-chip technology for the study of the female reproductive system	39
Biomaterial-based delivery of nucleic acids for tissue regeneration	38
Adherence to minimal experimental requirements for defining extracellular vesicles and their functions	38
Recent advances in chemical modifications of guide RNA, mRNA and donor template for CRISPR-mediated genome editing	38
Immunocompetent cancer-on-chip models to assess immuno-oncology therapy	37
Bacterial membrane vesicles for vaccine applications	37
Self-assembling peptides as vectors for local drug delivery and tissue engineering applications	37
Biomimetic immunomodulation strategies for effective tissue repair and restoration	37
Engineered bacterial membrane vesicles are promising carriers for vaccine design and tumor immunotherapy	37
Drug development of lyso-thermosensitive liposomal doxorubicin: Combining hyperthermia and thermosensitive drug delivery	37
Antimicrobial blue light: A ‘Magic Bullet’ for the 21st century and beyond?	37
Antifibrotic strategies for medical devices	37
Harnessing cerebrospinal fluid circulation for drug delivery to brain tissues	37
Inhalation delivery technology for genome-editing of respiratory diseases	36
Challenges and solutions in polymer drug delivery for bacterial biofilm treatment: A tissue-by-tissue account	36
Non-viral nanoparticles for RNA interference: Principles of design and practical guidelines	36
Mucosal drug delivery and 3D printing technologies: A focus on special patient populations	36
Sustained delivery approaches to improving adaptive immune responses	36
Polymers in pharmaceutical additive manufacturing: A balancing act between printability and product performance	36
Engineering and loading therapeutic extracellular vesicles for clinical translation: A data reporting frame for comparability	36
Role of extracellular vesicles in liver diseases and their therapeutic potential	36
The role of microneedle arrays in drug delivery and patient monitoring to prevent diabetes induced fibrosis	36
Particle engineering principles and technologies for pharmaceutical biologics	36
Decorated bacteria and the application in drug delivery	36
Advances in the treatment of inflammatory bowel disease: Focus on polysaccharide nanoparticulate drug delivery systems	36
Cancer-associated fibroblasts: Origin, function, imaging, and therapeutic targeting	36
Targeting the tumor biophysical microenvironment to reduce resistance to immunotherapy	36
Dynamic nanoassemblies of nanomaterials for cancer photomedicine	35
Versatility on demand – The case for semi-solid micro-extrusion in pharmaceutics	35
Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic/pharmacodynamic (PK/PD) models	35
Multifunctional plasmonic-magnetic nanoparticles for bioimaging and hyperthermia	35
Toward closed-loop drug delivery: Integrating wearable technologies with transdermal drug delivery systems	35
Ultrasound-mediated blood–brain barrier opening: An effective drug delivery system for theranostics of brain diseases	35
Drug release from in situ forming implants and advances in release testing	35
Coiled coil-based therapeutics and drug delivery systems	35
Advances on erythrocyte-mimicking nanovehicles to overcome barriers in biological microenvironments	35
Artificial intelligence and machine learning assisted drug delivery for effective treatment of infectious diseases	34
Merging data curation and machine learning to improve nanomedicines	34
Can microorganisms develop resistance against light based anti-infective agents?	34
Highly branched poly(β-amino ester)s for gene delivery in hereditary skin diseases	34
Two-dimensional nanomaterials for tumor microenvironment modulation and anticancer therapy	34
Controlling drug release with additive manufacturing-based solutions	33
Mechanisms of immune response to inorganic nanoparticles and their degradation products	33
Meet me halfway: Are in vitro 3D cancer models on the way to replace in vivo models for nanomedicine development?	33
Biodistribution, pharmacokinetics and excretion studies of intravenously injected nanoparticles and extracellular vesicles: Possibilities and challenges	33
Progress of engineered bacteria for tumor therapy	33
Enhancing the therapeutic use of biofilm-dispersing enzymes with smart drug delivery systems	33
Light-triggered photodynamic nanomedicines for overcoming localized therapeutic efficacy in cancer treatment	33
Nanotechnologies for the delivery of biologicals: Historical perspective and current landscape	33
Destruction of tumor vasculature by vascular disrupting agents in overcoming the limitation of EPR effect	33
Non-viral strategies for delivering genome editing enzymes	33